Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 11/20 | 0.58 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28349215 | 0.90 | FKBP1A (0.56) | FKBP1AACERENCTSKCTSL | |
| SCHEMBL15251714 | 0.88 | FKBP1A (0.54) | FKBP1AACERENCTSKCTSL | |
| SCHEMBL15251803 | 0.88 | ACE (0.59) | FKBP1AACEACE2 | |
| SCHEMBL15251802 | 0.88 | ACE (0.59) | FKBP1AACEACE2 | |
| SCHEMBL15251713 | 0.88 | FKBP1A (0.54) | FKBP1AACERENCTSKCTSL | |
| SCHEMBL13413216 | 0.87 | FKBP1A (0.53) | FKBP1AACERENCTSKCTSL | |
| SCHEMBL15251676 | 0.86 | FKBP1A (0.52) | FKBP1AACERENLMNACTSK | |
| SCHEMBL15251724 | 0.86 | FKBP1A (0.52) | FKBP1AACEREN | |
| SCHEMBL12191559 | 0.86 | FKBP1A (0.52) | FKBP1AACERENCTSKCTSL | |
| SCHEMBL15251708 | 0.86 | FKBP1A (0.52) | FKBP1AACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678765-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2010-03-16 | — | — | US | disclosed |
| US-7348310-B2 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A. (ES) | 2008-03-25 | — | — | US | disclosed |
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | PHARMA MAR, S.A., A SPAIN CORPORATION | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009435-A1 | Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them | MCL1, APLNR, PAICS | FKBP1A 3393/4885ACE 2441/4885REN 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.